Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
In a regulatory filing, Aarti Drugs said that the United States Food and Drug Administration (US FDA) has inspected the formulations (oncology) manufacturing facility of its subsidiary, Pinnacle Life Science at Baddi, Himachal Pradesh from 16 April 2024 to 22 April 2024.
On conclusion of the inspection, the company has received five inspectional observations in Form 483, where none of the observations are related to data integrity. The company will work closely with US FDA in resolving all points, the pharmaco stated in the press release.
?There is no impact on financial, operation or other activities of the company pursuant the observations received,? added the firm.
Aarti Drugs is primarily involved in manufacturing and marketing of active pharmaceutical ingredients (API), pharma intermediates and specialty chemicals.
The pharmaceutical company?s consolidated net profit rose marginally to Rs 36.67 crore in Q3 FY24 as compared with Rs 36.68 crore recorded in Q3 FY23. Revenue from operations fell 8.7% to Rs 605.94 crore in Q3 FY24 as compared with Rs 663.96 crore posted same period a year ago.
Shares of Aarti Drugs rose 1.14% to Rs 498.80 on the BSE.
Powered by Capital Market - Live News